World AIDS Day: SAMRC's Groundbreaking Study with MGI's DNBSEQ Technology
12/1/23
Offline
South Africa
Share
On December 1st, we acknowledged World AIDS Day, reflecting on global efforts and advancements in HIV/AIDS research.
A SAMRC (South African Medical Research Council) study explored rare HIV phenotypes in South Africa using MGI's DNBSEQ technology, Identifying specific genetic variations that may contribute to their exceptional immune response opens doors to new therapeutic strategies and personalized treatments that could benefit millions of people living with HIV.
On December 1st, we acknowledged World AIDS Day, reflecting on global efforts and advancements in HIV/AIDS research.
A SAMRC (South African Medical Research Council) study explored rare HIV phenotypes in South Africa using MGI's DNBSEQ technology, Identifying specific genetic variations that may contribute to their exceptional immune response opens doors to new therapeutic strategies and personalized treatments that could benefit millions of people living with HIV.
On December 1st, we acknowledged World AIDS Day, reflecting on global efforts and advancements in HIV/AIDS research.
A SAMRC (South African Medical Research Council) study explored rare HIV phenotypes in South Africa using MGI's DNBSEQ technology, Identifying specific genetic variations that may contribute to their exceptional immune response opens doors to new therapeutic strategies and personalized treatments that could benefit millions of people living with HIV.
On December 1st, we acknowledged World AIDS Day, reflecting on global efforts and advancements in HIV/AIDS research.
A SAMRC (South African Medical Research Council) study explored rare HIV phenotypes in South Africa using MGI's DNBSEQ technology, Identifying specific genetic variations that may contribute to their exceptional immune response opens doors to new therapeutic strategies and personalized treatments that could benefit millions of people living with HIV.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About MGI
MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.
MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.
The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.
For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.
About SAMRC
Established in 1969, South African Medical Research Council (SAMRC) is dedicated to improving South Africa's health through research, innovation, and technology transfer, covering laboratory investigations, clinical research, and public health studies. Focused on the quadruple burden of disease, their research informs policy, enhances practices, and uplifts the nation's health. As the largest local funder, SAMRC pioneers cutting-edge medical innovations, addressing genomic research, treatment regimens, vaccine development, diagnostics, and drug/device creation. Committed to transformation, SAMRC addresses disparities through various programs, ensuring sustainable health research capacity in South Africa. As custodians of health research, SAMRC builds a healthier nation through ongoing innovation. For more information, please visit the samrc.ac.za.
About SAMRC
Established in 1969, South African Medical Research Council (SAMRC) is dedicated to improving South Africa's health through research, innovation, and technology transfer, covering laboratory investigations, clinical research, and public health studies. Focused on the quadruple burden of disease, their research informs policy, enhances practices, and uplifts the nation's health. As the largest local funder, SAMRC pioneers cutting-edge medical innovations, addressing genomic research, treatment regimens, vaccine development, diagnostics, and drug/device creation. Committed to transformation, SAMRC addresses disparities through various programs, ensuring sustainable health research capacity in South Africa. As custodians of health research, SAMRC builds a healthier nation through ongoing innovation. For more information, please visit the samrc.ac.za.
About SAMRC
Established in 1969, South African Medical Research Council (SAMRC) is dedicated to improving South Africa's health through research, innovation, and technology transfer, covering laboratory investigations, clinical research, and public health studies. Focused on the quadruple burden of disease, their research informs policy, enhances practices, and uplifts the nation's health. As the largest local funder, SAMRC pioneers cutting-edge medical innovations, addressing genomic research, treatment regimens, vaccine development, diagnostics, and drug/device creation. Committed to transformation, SAMRC addresses disparities through various programs, ensuring sustainable health research capacity in South Africa. As custodians of health research, SAMRC builds a healthier nation through ongoing innovation. For more information, please visit the samrc.ac.za.
About SAMRC
Established in 1969, South African Medical Research Council (SAMRC) is dedicated to improving South Africa's health through research, innovation, and technology transfer, covering laboratory investigations, clinical research, and public health studies. Focused on the quadruple burden of disease, their research informs policy, enhances practices, and uplifts the nation's health. As the largest local funder, SAMRC pioneers cutting-edge medical innovations, addressing genomic research, treatment regimens, vaccine development, diagnostics, and drug/device creation. Committed to transformation, SAMRC addresses disparities through various programs, ensuring sustainable health research capacity in South Africa. As custodians of health research, SAMRC builds a healthier nation through ongoing innovation. For more information, please visit the samrc.ac.za.
DNBSEQ
COLLABORATION
WORLD AIDS DAY
SAMRC
HIV
Share this article :
Share
Nov 4, 2024
Join us for the Future of Omics Conference in Stockholm
Do you want to learn about innovative solutions within Next Generation Sequencing? On November 4th we are organizing our first Future of Omics Nordic Station at Karolinska Institute in Stockholm. Experience a day with insights from leading experts in the field, engage in discussions and valuable networking.
Sep 10, 2024
MGI Tech Unveils its SEQ ALL landscape at the Future of Omics Conference
Discover insights from the "Future of Omics" event, where leading experts discussed innovations in genomics, proteomics, and metabolomics. Explore key takeaways on advancing research and technology, shaping the future of personalized medicine and healthcare. Join us in celebrating the progress in omics!
Jun 1, 2024
MGI Tech Shares New Data on Core DNEBSEQ Technology and Showcases Latest Sequencing Innovations at ESHG 2024
MGI showcased its latest innovations at the ESHG 2024, highlighting the upgraded StandardMPS 2.0 sequencing chemistry and unveiling the new DNBelab C-TaiM 4 Single-Cell Droplet Generator. European researchers presented advancements in diagnostics, population health, and more.
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).
Join our newsletter to stay up to date on features and releases.
I have read and understood MGI’s Privacy Policy, and I consent to the collection and processing of my personal data for handling, responding to my contact, receiving your newsletter as well as promotion and marketing activities.
*For Research Use Only
Not for use in diagnostic procedures (except as specifically noted).